- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02488044
A Phase 1/2 Study of AEB1102 in Patients With Arginase 1 Deficiency
A Phase 1/2 Open-label Study in Patients With Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
A Phase 1/2 Open-label Study in Patients with Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102. This study is designed to evaluate the safety and tolerability of IV administration of AEB1102 for the treatment of pediatric and adult patients with Arginase 1 deficiency and hyperargininemia. This study will be conducted in 2 parts: Part 1 (Single Ascending Dose Escalation) and Part 2 (Repeated Dosing). Each part will be preceded by a baseline assessment of arginine levels. All patients who participate in Part 1 may continue AEB1102 dosing in Part 2 if they qualify for continued dosing. A data safety monitoring board (DSMB) will provide independent review of study safety data and recommend whether the sponsor should continue the study as planned, modify the study protocol, or discontinue the study.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Porto, Portogallo
- Centro Hospitalar S. Joao
-
-
-
-
-
London, Regno Unito
- Great Ormond Street Hospital
-
-
-
-
California
-
Stanford, California, Stati Uniti, 94305
- Stanford University School of Medicine
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32611
- University of Florida
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Children's Hospital of Michigan
-
-
New York
-
New York, New York, Stati Uniti, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- UTSW
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- Seattle Children's Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female ≥ 2 years
- Documented diagnosis of Arginase 1 deficiency
- Adequate organ function as defined by laboratory assessment
- If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
- If a sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
- Patient or legal guardian is able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification) prior to any screening procedures
Exclusion Criteria:
- Transfusion of ≥ 2 units of RBCs within 60 days
- Active infection requiring systemic treatment
- Known infection with HIV, Hep B or Hep C
- Unstable hyperammonemia requiring hospitalization within 14 days
- Has a history of hypersensitivity to PEG or any other component of the AEB1102 (Co-ArgI-PEG) formulation
- If female, is lactating or breast feeding
PART 2 INCLUSION CRITERION:
1. Did not experience any safety or tolerability event in Part 1 which would preclude continued participation and dosing of AEB1102
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: AEB1102
AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks. Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy. |
modified human arginase I
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants With Adverse Events Related to ECGs
Lasso di tempo: Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
The primary means of assessing ECG results was through assessing AEs related to ECGs. |
Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
|
Number of Participants With Adverse Events Related to Clinical Laboratory Results
Lasso di tempo: Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
The primary means of assessing clinical laboratory results was through assessing AEs related to clinical laboratory results. Laboratory studies included hematology, chemistry, urinalysis, and coagulatio. |
Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pharmacokinetic Profile of IV AEB1102: Time of the Maximum Observed Concentration (Tmax)
Lasso di tempo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Area Under the Curve Through the Time of the Last Measurable Concentration (AUC0-t)
Lasso di tempo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Maximum Observed Concentration (Cmax)
Lasso di tempo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Apparent Terminal Elimination Half-life (T1/2)
Lasso di tempo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Area Under the Curve Extrapolated to Infinity (AUC0-∞)
Lasso di tempo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Serum Clearance (CL)
Lasso di tempo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Volume of Distribution (Vss)
Lasso di tempo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Plasma Arginine Concentrations After AEB1102 IV
Lasso di tempo: 168 hrs post dose, Part 2: Change from Baseline to 8 weeks
|
Plasma arginine concentration post dose AEB1102 IV |
168 hrs post dose, Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: Guanidinoacetic Acid (GAA)
Lasso di tempo: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: α-keto-δ-guanidinovaleric Acid (GVA)
Lasso di tempo: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: Argininic Acid (ARGA)
Lasso di tempo: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: N-α-acetyl-L-arginine (NAA)
Lasso di tempo: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Direttore dello studio: Mattias Rudebeck, PhD MSc BMedSc, Immedica Pharma AB
Pubblicazioni e link utili
Pubblicazioni generali
- Diaz GA, Schulze A, McNutt MC, Leao-Teles E, Merritt JL 2nd, Enns GM, Batzios S, Bannick A, Zori RT, Sloan LS, Potts SL, Bubb G, Quinn AG. Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency. J Inherit Metab Dis. 2021 Jul;44(4):847-856. doi: 10.1002/jimd.12343. Epub 2021 Jan 26.
- Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. Mol Genet Metab. 2005 Mar;84(3):243-51. doi: 10.1016/j.ymgme.2004.11.004. Epub 2004 Dec 19.
- Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, Curley SA. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol. 2011 Jun;4(3):138-46. doi: 10.1593/tlo.10265. Epub 2011 Jun 1.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Metabolismo, errori congeniti
- Malattie genetiche, congenite
- Malattie metaboliche
- Malattie cerebrali, metaboliche, congenite
- Malattie cerebrali, metaboliche
- Metabolismo degli aminoacidi, errori congeniti
- Disturbi del ciclo dell'urea, congeniti
- Malattie e anomalie congenite, ereditarie e neonatali
- Malattie nutrizionali e metaboliche
- Iperargininemia
Altri numeri di identificazione dello studio
- CAEB1102-101A
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .